• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Eli Lilly to cut 8% of workforce in cost-cutting effort

September 7, 2017 By Sarah Faulkner

Eli LillyEli Lilly (NYSE:LLY) said today that it plans to shed 3,500 positions globally as it works to cut costs.

The drugmaker estimates that the move will result in yearly savings of about $500 million, starting next year.

Lilly said most of the cuts will come from a voluntary early-retirement program that it is offering the U.S., but it is also shuttering a plant in Iowa and R&D offices in New Jersey and China.

“We have an abundance of opportunities—eight medicines launched in the past four years and the potential for two more by the end of next year,” chairman & CEO David Ricks said in prepared remarks. “To fully realize these opportunities and invest in the next generation of new medicines, we are taking action to streamline our organization and reduce our fixed costs around the world.”

“The actions we are announcing today will result in a leaner, more nimble global organization and will accelerate progress towards our long-term goals of growing revenue, expanding operating margins and sustaining the flow of life-changing medicines from our pipeline.”

The company has had an array of setbacks this year, including what will likely add up to a multi-year delay for its investigational rheumatoid arthritis drug, baricitinib. The FDA declined to approve that drug and has asked the company to conduct an additional clinical trial.

That decision came on the heels of Lilly’s experimental Alzheimer’s treatment failing in a clinical trial. The company had hoped that it would prove to be the first drug approved to slow progression of the neurological disease.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Business/Financial News, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Eli Lilly & Co.

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS